HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
The approval process for new cancer therapies involves navigating complex regulatory frameworks, which vary across regions. Regulatory bodies such as the FDA, EMA, and other national agencies scrutinize safety, efficacy, and manufacturing standards. Clinical trials often face delays due to the rigorous documentation and review processes. The challenge is further amplified by evolving scientific understanding, where regulators must balance innovation with safety. Streamlining these processes without compromising patient safety can accelerate the availability of new treatments. Furthermore, the increasing complexity of combination therapies and personalized medicine requires regulatory agencies to adapt and develop new guidelines, ensuring that patients have access to the most effective and timely therapies.
